AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation

Kidney Transplant Failure and Rejection Clinical Trial

— All-MAP  

Official title:

AlloSure and AlloMap for the Monitoring of Antibody Mediated Processes After Kidney Transplantation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04057742
• Other study ID #: 2019-0750
• Secondary ID: 1K23DK122136-01A
• Status: Active, not recruiting
• Start date: October 7, 2019
• Est. completion date: August 2024

Study information

• Verified date: December 2023
• Source: University of Wisconsin, Madison
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective cohort observational study to assess the role of AlloSure Donor Derived Cell Free DNA (ddcfDNA) assay in the monitoring of three high-risk groups of kidney transplant patients for antibody mediated processes.

• Group A. Thirty participants with a positive Virtual Cross-Match (VXM) at the time of transplant will be monitored for 12 months

• Group B. Similarly, 24 participants with dnDSA will undergo a SOC biopsy within approximately three months to determine the incidence of Active Antibody Mediated Rejection (AMR)

• Group C. 15 additional participants with the diagnosis of Chronic Active Antibody Mediated Rejection (cAMR) will undergo standard of care therapy and be monitored for treatment response with a follow-up biopsy at three months

Description:

This is a prospective cohort observational study to assess the role of AlloSure Donor Derived Cell Free DNA (ddcfDNA) assay in the monitoring of three high-risk groups of patients for antibody mediated processes.

The AlloSure assay will be combined with the AlloMAP assay (PAXgene blood sample); which is the first in history FDA-cleared genomic solid organ transplantation rejection blood test (AlloMap). Immune cell phenotypes and inflammatory cytokines will be examined. The combination of the three assays will provide a comprehensive molecular diagnostic and prognostic approach to antibody-mediated processes after renal transplantation. Additionally, formalin fixed paraffin embedded (FFPE) samples from kidney biopsies for subjects in all groups will be used to validate the nCounter platform. 3 slides from each biopsy will be sent to CareDx to be examined on the nCounter system. Other routine clinical data will be examined and assessed for correlation with the nCounter results. This will include AlloSure, Molecular Microscope, eGFR, creatinine, DSA as well as other key data fields taken from the Electronic Medical Record (EMR).

AlloMap Kidney is a lab-developed test and will be provided by CareDx, Inc. located at Brisbane, CA, and is designed, manufactured and used within a single CareDx laboratory. AlloMap Kidney is currently provided as "For Research use only" test and results are not intended for clinical diagnosis or patient management for "KidneyCare", which is the AlloSure-Kidney and AlloMap-Kidney tests combined.

• Group A. Thirty participants with a positive VXM at the time of transplant will be monitored for 12 months and undergo protocol biopsies on months 3 and 12 to detect subclinical rejection. Participants may also undergo clinically indicated biopsies for suspicion of rejection. AlloSure, AlloMap, immune cell phenotypes, and inflammatory cytokines will be measured at baseline (within 48 hours of transplant), 3 weeks, 6 weeks, 3M (SOC biopsy), 6M, 12M (SOC biopsy) and additionally at the time of any indication biopsy (5-7 time points/patient). Subjects in this group will be monitored for 12 months.

• Group B. Similarly, 24 participants with dnDSA will undergo a SOC biopsy within approximately three months to determine the incidence of AMR. Immune cell phenotyping, AlloSure and AlloMap will be measured at the time of the SOC biopsy (1 timepoint/patient). This is a single-time point study, unless participants are diagnosed with AMR and require treatment. In this case, they would be enrolled in group C (see below).

• Group C. 15 additional participants with the diagnosis of cAMR will undergo standard of care therapy and be monitored for treatment response with a follow-up biopsy at three months. Immune cell phenotyping, AlloSure and AlloMap will be used at baseline (prior to index biopsy) and 3M (follow-up surveillance biopsy) (2 timepoints/patient). Participants in this group will be monitored per SOC for three months (time between the two biopsies).

For all three groups, history and physical, blood draws and urine sample collections are performed per SOC. The only addition is blood sample collection and additional urine collection at the indicated SOC timepoints for AlloSure, AlloMap, immune cell flow cytometry, RNA-signatures, and inflammatory cytokines. In addition, leftover pathology slides that are stored in the pathology department will be sent out to CareDx for the purposes of performing the NanoString analysis. The slides will be returned to the pathology department after the NanoString analysis is complete.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 53
• Est. completion date: August 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Kidney transplant recipients (de novo or retransplant)

• Positive Virtual Crossmatch at transplant (Group A)

• Undergoing SOC biopsy for dnDSA (Group B)

• Proven cAMR (Group C)

Exclusion Criteria:

• Multi-Visceral transplant

• Contraindication to renal biopsy

Related Conditions & MeSH terms

• Kidney Transplant Failure and Rejection

Intervention

Diagnostic Test:
• AlloSure ddcfDNA assay
2.5 mL collection for Donor Derived Cell Free DNA at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C
• AlloMap assay
10 mL collection PAXgene blood sample at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C
• Inflammatory Cytokines
10 mL collection at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A
• Immune Cell Phenotypes
Collection of up to 1 cup of urine for per participant each study visit

Locations

Country	Name	City	State
United States	University of Wisconsin - Madison	Madison	Wisconsin

Sponsors (3)

Lead Sponsor	Collaborator
University of Wisconsin, Madison	CareDx, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Biopsy Confirmed AMR	To determine whether AlloSure, immune cell phenotypes, and inflammatory cytokines predict the incidence of AMR, the outcome measure will be incidence of biopsy confirmed AMR. For participants with a positive virtual crossmatch (group A), protocol biopsies are performed at 3 and 12 months posttransplant. For participants with De novo donor specific antibodies (dnDSA) (group B), protocol biopsies are performed within 3 months.	up to 12 months post-transplant
Secondary	Banff Pathology	To determine whether AlloSure and immune cell phenotyping predict the course of disease and/or response to treatment in participants with cAMR (Group C) the Banff pathology will be assessed.	up to 3 months following initial diagnosis of cAMR
Secondary	Renal Allograft Function: Concentration of Serum Creatinine (sCr)	To determine whether AlloSure predicts the course of disease and/or response to treatment in participants with cAMR, renal allograft function will be assessed by measuring sCR at baseline (index biopsy) and up to 3 months following SOC biopsy-proven cAMR.	up to 3 months following initial diagnosis of cAMR
Secondary	Renal Allograft Function: Estimated Glomerular Filtration Rate (eGFR)	To determine whether AlloSure predicts the course of disease and/or response to treatment in participants with cAMR, renal allograft function will be assessed by measuring eGFR at baseline (index biopsy) and up to 3 months following SOC biopsy-proven cAMR.	up to 3 months following initial diagnosis of cAMR
Secondary	Renal Allograft Function: Urinary Protein to Creatinine Ratio (UPC)	To determine whether AlloSure predicts the course of disease and/or response to treatment in participants with cAMR, renal allograft function will be assessed by measuring UPC at baseline (index biopsy) and up to 3 months following SOC biopsy-proven cAMR.	up to 3 months following initial diagnosis of cAMR
Secondary	Percent of Biopsy Samples Measured on Nanostring nCounter That Validate Clinical Outcomes	Validation of Nanostring nCounter platform using FFPE kidney biopsy tissue to assess tissue GEP in the context of Allograft Rejection in Groups A, B, and C.; GEP will be measured on the FFPE tissue to assess the patterns associated with allograft rejection. Samples will be retrospectively analysed from historic kidney biopsies performed, where the clinical diagnosis and outcome is known. Results will be compared to the gold standard of histopathology analysis.	experiment performed within 7 days of receiving sample
Secondary	Number of Genes Upregulated in Allograft Rejection	GEP analysis of FFPE tissue will be analysed to identify what pattern of genes are involved with different types of rejection and see whether the platform matches what has already been published in the literature.	experiment performed within 7 days of receiving sample
Secondary	Number of Genes Upregulated for BK Virus as determined by Nanostring nCounter	Genes within the Nanostring panel are associated with BK infection, will be examined with FFPE tissue taken from participants who had clinical BK infection.	experiment performed within 7 days of receiving sample

External Links

•   Banff Foundation for Allograft Pathology